DekaBank Deutsche Girozentrale
CRSP icon

DekaBank Deutsche Girozentrale’s CRISPR Therapeutics CRSP Stock Holding History

DekaBank Deutsche Girozentrale’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-40,745
Closed -$2.4M – 1170
2025
Q4 		$2.4M Hold
40,745
– – ﹤0.01% 731
2025
Q3 		$2.61M Hold
40,745
– – ﹤0.01% 702
2025
Q2 		$2.01M Hold
40,745
– – ﹤0.01% 741
2025
Q1 		$2.81M Hold
40,745
– – 0.01% 672
2024
Q4 		$2.09M Hold
40,745
– – ﹤0.01% 737
2024
Q3 		$2.18M Hold
40,745
– – ﹤0.01% 740
2024
Q2 		$2.26M Hold
40,745
– – ﹤0.01% 739
2024
Q1 		$2.81M Buy
40,745
+745
+2% +$53.3K 0.01% 692
2023
Q4 		$2.57M Hold
40,000
– – 0.01% 726
2023
Q3 		$1.83M Hold
40,000
– – ﹤0.01% 762
2023
Q2 		$2.28M Buy
40,000
+20,000
+100% +$1.13M 0.01% 721
2023
Q1 		$883K Sell
20,000
-843
-4% -$40.9K ﹤0.01% 899
2022
Q4 		$841K Buy
20,843
+843
+4% +$44.7K ﹤0.01% 923
2022
Q3 		$1.3M Sell
20,000
-25,660
-56% -$1.86M ﹤0.01% 808
2022
Q2 		$2.88M Hold
45,660
– – 0.01% 646
2022
Q1 		$2.93M Buy
45,660
+10,500
+30% +$659K 0.01% 676
2021
Q4 		$2.7M Sell
35,160
-15,650
-31% -$1.37M 0.01% 708
2021
Q3 		$5.6M Buy
50,810
+6,000
+13% +$754K 0.02% 509
2021
Q2 		$6.74M Buy
44,810
+8,500
+23% +$1.03M 0.02% 455
2021
Q1 		$4.18M Buy
36,310
+20,000
+123% +$3.02M 0.01% 533
2020
Q4 		$2.57M Buy
16,310
+2,860
+21% +$338K 0.01% 608
2020
Q3 		$1.14M Buy
+13,450
New +$1.19M 0.01% 723

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $23.7B AUM 65.43% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
GP
GSK plc London $599M AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $915M AUM 209.71% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

DekaBank Deutsche Girozentrale's CRSP Position: Q1 2026 in Review

DekaBank Deutsche Girozentrale sold out of CRISPR Therapeutics (CRSP) in Q1 2026, closing a stake of 40,745 shares — an estimated $2.4M sold.

DekaBank Deutsche Girozentrale first reported a position in CRSP in Q3 2020 and held it in 22 quarters. The position peaked at $6.74M in Q2 2021. 490 funds tracked by Wall St. Rank hold CRSP as of Q1 2026.

  • DekaBank Deutsche Girozentrale reported no remaining CRISPR Therapeutics position as of Q1 2026 after selling out during the quarter.
  • DekaBank Deutsche Girozentrale sold 40,745 CRISPR Therapeutics shares in Q1 2026, an estimated $2.4M.
  • DekaBank Deutsche Girozentrale first reported a position in CRISPR Therapeutics in Q3 2020 and held it in 22 quarters.
  • DekaBank Deutsche Girozentrale's CRISPR Therapeutics position peaked at $6.74M in Q2 2021.
  • 490 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q1 2026.

Based on DekaBank Deutsche Girozentrale's 13F filing for Q1 2026, filed 7 May 2026.